Advisory - Two lots of Advil Cold & Sinus Day/Night Convenience Pack recalled due to labelling error that may cause confusion between daytime and nighttime tablets
OTTAWA, ON, Oct. 3, 2021 /CNW/ -
Summary
Product: Advil Cold & Sinus Day/Night Convenience Pack, in boxes of 18 caplets and 36 caplets
Issue: GSK is recalling two lots (ER2072, ER2069, expiry 2023-02) due to a labelling error on the back of the blister pack. Consumers may take a nighttime caplet instead of a daytime caplet, and vice versa. Taking a nighttime caplet when alertness is required may pose health risks.
What to do: Stop using the recalled products. Consult a health care professional if you have used any of these products and have health concerns.
Issue GlaxoSmithKline Consumer Healthcare ULC (GSK) is recalling two lots of Advil Cold & Sinus Day/Night Convenience Pack (one lot of 18 caplet boxes and one lot of 36 caplet boxes) due to a labelling error on blister packs. The foil backing on the blister pack is rotated upside down and misaligned, so the nighttime caplets are labelled as daytime caplets, and some daytime caplets are labelled as nighttime caplets. Consumers may take a nighttime caplet when they intend to take a daytime caplet, and vice versa.
The daytime and nighttime caplets have a different shape and colour (the daytime caplet is beige and has the marking 'ADVIL COLD & SINUS' in black ink. The nighttime caplet is orange and has the marking 'Advil A/S'). The nighttime caplets contain an antihistamine medicinal ingredient (chlorpheniramine maleate) that can cause drowsiness. Taking a nighttime caplet when alertness is required may pose potentially serious adverse health consequences, such as when driving motor vehicles or operating heavy machinery. It may also cause potentially serious health consequences for those who have taken other sedatives or tranquilizers, consumed alcohol, and the elderly.
The affected products were distributed in Canada starting July 2021.
Health Canada is monitoring the company's recall and implementation of any necessary corrective and preventive actions.
Affected products
Product Name
DIN
Lot #
Expiration Date
Advil Cold & Sinus Day/Night Convenience Pack
Box of 36 caplets (24 daytime and 12 nighttime)
02399733 (convenience pack)
02267616 (daytime caplets)
02267632 (nighttime caplets)
ER2072
2023-02
Advil Cold & Sinus Day/Night Convenience Pack
Box of 18 caplets (12 daytime and 6 nighttime)
ER2069
2023-02
What you should do
Stop using the recalled products. Consult a health care professional if you have used any of these products and have health concerns.
Follow municipal or regional guidelines on how to dispose of chemicals and other hazardous waste; or
Return the product to your local pharmacy for proper disposal.
Contact GSK by calling 1-855-367-7349, or emailing [email protected], if you have questions about the recall.
Incorrectly labelled Advil Cold & Sinus Day/Night Convenience Pack blister pack, front and back. The top row contains orange nighttime caplets, followed by two rows of beige daytime caplets. The foil backing on the blister pack is rotated upside down and misaligned, so the nighttime caplets are labelled as daytime caplets, and some daytime caplets are labelled as nighttime caplets.
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...